| Literature DB >> 16434127 |
Susanna J Dunachie1, Michael Walther, Jenni M Vuola, Daniel P Webster, Sheila M Keating, Tamara Berthoud, Laura Andrews, Philip Bejon, Ian Poulton, Geoffrey Butcher, Katherine Watkins, Robert E Sinden, Amanda Leach, Philippe Moris, Nadia Tornieporth, Joerg Schneider, Filip Dubovsky, Eveline Tierney, Jack Williams, D Gray Heppner, Sarah C Gilbert, Joe Cohen, Adrian V S Hill.
Abstract
Heterologous prime-boost immunisation with RTS,S/AS02A and the poxvirus MVA-CS was evaluated in 18 healthy malaria-naïve subjects in Oxford. Both priming with RTS,S and boosting MVA-CS, and the reverse, were found to be safe and well tolerated. T cell responses as measured by IFN-gamma ex vivo ELISPOT were induced, but the responses were low to moderate in both groups, with heterologous boosting yielding only small increments in T cell immunogenicity and no increased antibody response. Protection against 3D7 Plasmodium falciparum sporozoite challenge 4 weeks after the final vaccination was equal for both regimens at 33% (95% C.I. 4.3-77.7%), with one subject remaining fully protected on rechallenge at 5 months.Entities:
Mesh：
Substances：
Year: 2006 PMID： 16434127 DOI： 10.1016/j.vaccine.2005.12.041
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641